iDNA Genomics Public (CYS:IDNA) EBIT: € Mil (TTM As of . 20)


CYS:IDNA iDNA Genomics Public Ltd CYS:IDNA
23 GF Score
Price €22.80
! 2 Warning Signs
View Full Analysis

What is iDNA Genomics Public EBIT?

iDNA Genomics Public CYS:IDNA 23 EBIT is € Mil as of . 20. GuruFocus rates CYS:IDNA with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

iDNA Genomics Public's earnings before interest and taxes (EBIT) for the six months ended in . 20 was €0.00 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

iDNA Genomics Public  (CYS:IDNA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

iDNA Genomics Public's annualized ROC % for the quarter that ended in . 20 is calculated as:

ROC % (Q: . 20 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: . 20 ) + Invested Capital (Q: . 20 ))/ count )
= * ( 1 - % )/( ( + )/ )
=/
= %

where

Invested Capital(Q: . 20 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
= - - ( - max(0, - +))
=

Invested Capital(Q: . 20 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
= - - ( - max(0, - +))
=

Note: The Operating Income data used here is one times the annual (. 20) data.

2. Joel Greenblatt's definition of Return on Capital:

iDNA Genomics Public's annualized ROC (Joel Greenblatt) % for the quarter that ended in . 20 is calculated as:

ROC (Joel Greenblatt) %(Q: . 20 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: . 20  Q: . 20
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=/( ( ( + max(, 0)) + ( + max(, 0)) )/ )
=/( ( + )/ )
=/
= %

where Working Capital is:

Working Capital(Q: . 20 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=( + + ) - ( + + )
=

Working Capital(Q: . 20 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=( + + ) - ( + + )
=

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (. 20) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

iDNA Genomics Public's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: . 20 )
=/0.000
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

iDNA Genomics Public EBIT Related Terms

iDNA Genomics Public EBIT Historical Data

* Premium members only.

The historical data trend for iDNA Genomics Public's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

iDNA Genomics Public EBIT Chart

iDNA Genomics Public Annual Data
Trend
EBIT

iDNA Genomics Public Semi-Annual Data
EBIT

CYS:IDNA vs : EBIT Comparison

For the Diagnostics & Research subindustry, iDNA Genomics Public's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

iDNA Genomics Public EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, iDNA Genomics Public's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where iDNA Genomics Public's EV-to-EBIT falls into.


CYS:IDNA
23GF Score
iDNA Genomics Public Ltd CYS:IDNA
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

iDNA Genomics Public EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in . 20 was € Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of € Mil mean?
iDNA Genomics Public (CYS:IDNA) has a EBIT of € Mil as of . 20. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on iDNA Genomics Public.
Is iDNA Genomics Public's EBIT too high?
iDNA Genomics Public's current EBIT is € Mil. Overall, iDNA Genomics Public has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does iDNA Genomics Public's EBIT compare to ?
iDNA Genomics Public's EBIT of € Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on iDNA Genomics Public. iDNA Genomics Public's current EBIT is € Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iDNA Genomics Public stock overvalued right now?
iDNA Genomics Public (CYS:IDNA) has a current EBIT of € Mil. The current EBIT is € Mil. iDNA Genomics Public's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For iDNA Genomics Public (CYS:IDNA), the current EBIT is € Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

iDNA Genomics Public Business Description

Comparable Companies
Address 7 Hatzidaki Street, Trypiotis, Nicosia, CYP, 1066
iDNA Genomics Public Ltd operates in the field of genomics and biotechnology and specializes in personalized health care. Its purpose is to develop and provide genetic tests in the field of genomics, through professionals (Medical Genomics) and directly to the consumer (Direct-to-Consumer Genomics).
23GF Score

Get the complete analysis for CYS:IDNA

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€22.80
Price